Emmendingen, Germany

Spyridon Marinis

This inventor holds 2 USPTO granted patents. Top assignee: Warner-Lambert Company. Active years: 1976.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1976

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Spyridon Marinis: Innovator in Antimicrobial Pharmaceuticals

Introduction

Spyridon Marinis is a notable inventor based in Emmendingen, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antimicrobial agents. With a total of 2 patents to his name, Marinis continues to push the boundaries of innovation in his field.

Latest Patents

Marinis's latest patents include a novel invention related to 1-(aryl)-2-(arylalkyl)-3-(or-4-)-[4'-(substituted alkyl-)-piperazino-1']-butanols-2 and butenes-1, which demonstrate antimicrobial action. These inventions also encompass their pharmaceutically acceptable salts and the processes for their manufacture. The significance of these patents lies in their potential applications in combating microbial infections.

Career Highlights

Spyridon Marinis is currently associated with Warner-Lambert Company, where he applies his expertise in pharmaceutical innovation. His work has been instrumental in advancing the development of new antimicrobial compounds that can improve health outcomes.

Collaborations

Marinis collaborates with various professionals in the field, including his coworker Wolf-Dieter Vigelius. These collaborations enhance the research and development process, leading to more effective pharmaceutical solutions.

Conclusion

Spyridon Marinis is a dedicated inventor whose work in antimicrobial pharmaceuticals is paving the way for new treatments. His contributions are vital to the ongoing fight against microbial resistance and highlight the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…